All In Biotech

Investigational drug · Phase 2

Extended Phase

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Polycythemia Vera (PV).

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3,241

Any phase or sponsor naming "Extended Phase"

First trial start

2025

Sep 23, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Extended Phase", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Polycythemia Vera (PV)

Approved drugs for the same conditions: Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Extended Phase" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 453 on PubMed

Also in development for Polycythemia Vera (PV)

  • FlonoltinibPhase 34 trials

    Chengdu Zenitar Biomedical Technology Co., Ltd · MF, MF,PMF,PPV-MF,PET-MF, Polycythemia Vera (PV)

  • DISC-3405Phase 21 trial

    Disc Medicine, Inc · Polycythemia Vera (PV)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.